BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 31555483)

  • 1. Elevated CRP levels indicate poor progression-free and overall survival on cancer patients treated with PD-1 inhibitors.
    Iivanainen S; Ahvonen J; Knuuttila A; Tiainen S; Koivunen JP
    ESMO Open; 2019; 4(4):e000531. PubMed ID: 31555483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. C-Reactive Protein (CRP) Levels in Immune Checkpoint Inhibitor Response and Progression in Advanced Non-Small Cell Lung Cancer: A Bi-Center Study.
    Riedl JM; Barth DA; Brueckl WM; Zeitler G; Foris V; Mollnar S; Stotz M; Rossmann CH; Terbuch A; Balic M; Niedrist T; Bertsch T; Stoeger H; Pichler M; Olschewski H; Absenger G; Ficker JH; Gerger A; Posch F
    Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32824580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of preoperative serum CRP with PD-L1 expression in 508 patients with non-small cell lung cancer: A comprehensive analysis of systemic inflammatory markers.
    Akamine T; Takada K; Toyokawa G; Kinoshita F; Matsubara T; Kozuma Y; Haratake N; Takamori S; Hirai F; Tagawa T; Okamoto T; Yoneshima Y; Okamoto I; Shimokawa M; Oda Y; Nakanishi Y; Maehara Y
    Surg Oncol; 2018 Mar; 27(1):88-94. PubMed ID: 29549910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical value of neutrophil-to-lymphocyte ratio in patients with non-small-cell lung cancer treated with PD-1/PD-L1 inhibitors.
    Jiang T; Bai Y; Zhou F; Li W; Gao G; Su C; Ren S; Chen X; Zhou C
    Lung Cancer; 2019 Apr; 130():76-83. PubMed ID: 30885355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment discontinuation and re-initiation of anti-PD-(L)1 agents in metastatic cancers.
    Tikkanen A; Iivanainen S; Koivunen JP
    J Cancer Res Clin Oncol; 2020 Aug; 146(8):2153-2160. PubMed ID: 32306129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer.
    Mezquita L; Auclin E; Ferrara R; Charrier M; Remon J; Planchard D; Ponce S; Ares LP; Leroy L; Audigier-Valette C; Felip E; Zerón-Medina J; Garrido P; Brosseau S; Zalcman G; Mazieres J; Caramela C; Lahmar J; Adam J; Chaput N; Soria JC; Besse B
    JAMA Oncol; 2018 Mar; 4(3):351-357. PubMed ID: 29327044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors.
    Peng L; Wang Y; Liu F; Qiu X; Zhang X; Fang C; Qian X; Li Y
    Cancer Immunol Immunother; 2020 Sep; 69(9):1813-1822. PubMed ID: 32350592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Positive PD-L1 expression is predictive for patients with advanced EGFR wild-type non-small cell lung cancer treated with gemcitabine and cisplatin.
    Qiu Y; Jiang J; Zhang M; Qin Y
    Oncol Lett; 2019 Jul; 18(1):161-168. PubMed ID: 31289485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer.
    Bagley SJ; Kothari S; Aggarwal C; Bauml JM; Alley EW; Evans TL; Kosteva JA; Ciunci CA; Gabriel PE; Thompson JC; Stonehouse-Lee S; Sherry VE; Gilbert E; Eaby-Sandy B; Mutale F; DiLullo G; Cohen RB; Vachani A; Langer CJ
    Lung Cancer; 2017 Apr; 106():1-7. PubMed ID: 28285682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inflammation-nutritional markers of peripheral blood could predict survival in advanced non-small-cell lung cancer patients treated with PD-1 inhibitors.
    Pu D; Xu Q; Zhou LY; Zhou YW; Liu JY; Ma XL
    Thorac Cancer; 2021 Nov; 12(21):2914-2923. PubMed ID: 34581010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Impact of Neutrophil/Lymphocyte Ratio, Platelet Count, CRP, and Albumin Levels in Metastatic Colorectal Cancer Patients Treated with FOLFIRI-Bevacizumab.
    Artaç M; Uysal M; Karaağaç M; Korkmaz L; Er Z; Güler T; Börüban MC; Bozcuk H
    J Gastrointest Cancer; 2017 Jun; 48(2):176-180. PubMed ID: 27714653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study.
    Russo A; Russano M; Franchina T; Migliorino MR; Aprile G; Mansueto G; Berruti A; Falcone A; Aieta M; Gelibter A; Russo A; Barni S; Maio M; Martelli O; Pantano F; Iacono D; Calvetti L; Quadrini S; Roca E; Vasile E; Imperatori M; Occhipinti M; Galvano A; Petrelli F; Calabrò L; Pasquini G; Intagliata S; Ricciardi GRR; Tonini G; Santini D; Adamo V
    Adv Ther; 2020 Mar; 37(3):1145-1155. PubMed ID: 32002809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD8
    Duchemann B; Naigeon M; Auclin E; Ferrara R; Cassard L; Jouniaux JM; Boselli L; Grivel J; Desnoyer A; Danlos FX; Mezquita L; Caramella C; Marabelle A; Besse B; Chaput N
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35131864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pretreatment prognostic nutritional index as a novel biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
    Shoji F; Takeoka H; Kozuma Y; Toyokawa G; Yamazaki K; Ichiki M; Takeo S
    Lung Cancer; 2019 Oct; 136():45-51. PubMed ID: 31437663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis.
    Duruisseaux M; Martínez-Cardús A; Calleja-Cervantes ME; Moran S; Castro de Moura M; Davalos V; Piñeyro D; Sanchez-Cespedes M; Girard N; Brevet M; Giroux-Leprieur E; Dumenil C; Pradotto M; Bironzo P; Capelletto E; Novello S; Cortot A; Copin MC; Karachaliou N; Gonzalez-Cao M; Peralta S; Montuenga LM; Gil-Bazo I; Baraibar I; Lozano MD; Varela M; Ruffinelli JC; Palmero R; Nadal E; Moran T; Perez L; Ramos I; Xiao Q; Fernandez AF; Fraga MF; Gut M; Gut I; Teixidó C; Vilariño N; Prat A; Reguart N; Benito A; Garrido P; Barragan I; Emile JF; Rosell R; Brambilla E; Esteller M
    Lancet Respir Med; 2018 Oct; 6(10):771-781. PubMed ID: 30100403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peripheral blood biomarkers correlate with outcomes in advanced non-small cell lung Cancer patients treated with anti-PD-1 antibodies.
    Soyano AE; Dholaria B; Marin-Acevedo JA; Diehl N; Hodge D; Luo Y; Manochakian R; Chumsri S; Adjei A; Knutson KL; Lou Y
    J Immunother Cancer; 2018 Nov; 6(1):129. PubMed ID: 30470260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of PD-L1 expression and NLR as prognostic marker in patients with surgically resected non-small cell lung cancer.
    Wang X; Cao L; Li S; Wang F; Huang D; Jiang R
    J Cancer; 2019; 10(26):6703-6710. PubMed ID: 31777599
    [No Abstract]   [Full Text] [Related]  

  • 19. Development of nomograms to predict therapeutic response and prognosis of non-small cell lung cancer patients treated with anti-PD-1 antibody.
    Yuan S; Xia Y; Shen L; Ye L; Li L; Chen L; Xie X; Lou H; Zhang J
    Cancer Immunol Immunother; 2021 Feb; 70(2):533-546. PubMed ID: 32852602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. C-reactive protein and neutrophil-lymphocyte ratio are prognostic in metastatic clear-cell renal cell carcinoma patients treated with nivolumab.
    Roussel E; Kinget L; Verbiest A; Debruyne PR; Baldewijns M; Van Poppel H; Albersen M; Beuselinck B
    Urol Oncol; 2021 Apr; 39(4):239.e17-239.e25. PubMed ID: 33485762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.